Abiopharma

🔍 Walsh Derrick (Executive)

Company: Axos Financial, Inc. (AX)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 1,360 shares of Common Stock at $82.93 per share (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,886.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 733 shares of Common Stock at $82.93 per share (Direct)
  Date: 2026-03-20 | Code: D | equity_swap_involved: 0 | shares_owned_after: 40,153.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: H | nature_of_ownership: 401(k) Plan | shares_owned_after: 2,869.00
• Sold 1,360 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 178,835.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5, F5

Footnotes:

• F1: Represents shares of Common Stock issued on March 20, 2026, following the vesting of Restricted Stock Units ("RSUs") which vest as to one-third of the shares on each anniversary of the date of grant. The RSUs were previously granted to the reporting person under the Axos Financial, Inc. 2014 Amended and Restated 2014 Stock Incentive Plan.
• F2: Represents shares of Common Stock retained by Axos Financial, Inc. for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vested RSUs.
• F3: The RSUs were granted to the reporting person under the Axos Financial, Inc. 2014 Stock Incentive Plan. The RSUs are accompanied by dividend equivalent rights.
• F4: Each RSU represents a contingent right to receive one share of Axos Financial, Inc. Common Stock.
• F5: The RSUs vest as to one-third of the shares on each anniversary date of grant.